These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 32954860)

  • 1. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 4. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
    Mithoefer MC; Grob CS; Brewerton TD
    Lancet Psychiatry; 2016 May; 3(5):481-8. PubMed ID: 27067625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Field of Psychedelic Psychotherapy.
    Barber GS; Aaronson ST
    Curr Psychiatry Rep; 2022 Oct; 24(10):583-590. PubMed ID: 36129571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988926
    [No Abstract]   [Full Text] [Related]  

  • 10. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
    Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
    Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with psilocybin: applications for patients with psychiatric disorders].
    Breeksema JJ; Koolen MHB; Somers M; Schoevers RA
    Ned Tijdschr Geneeskd; 2021 Jan; 165():. PubMed ID: 33560605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.